School of Pharmacy, University of Otago, Dunedin, New Zealand.
Int J Rheum Dis. 2010 Feb 1;13(1):48-54. doi: 10.1111/j.1756-185X.2009.01449.x.
To carry out a pilot study to investigate the effect of short-term oral probiotic administration on the metabolism of sulfasalazine (SSZ) in patients with rheumatoid arthritis (RA) stabilized on SSZ.
Twelve subjects with RA taking stable doses of SSZ for a minimum of 3 months prior to the study, received a probiotic preparation contained three strains of bacteria (1.8 x 10(9) CFU/day) twice daily for 1 week. Single point blood and 12-h urine samples were taken before and after probiotic treatment and 3 weeks following discontinuation of probiotics, for determination of SSZ and its metabolites. The presence of the probiotic bacteria in the feces of patients was investigated by denaturing gradient gel electrophoresis (DGGE).
Adverse events recorded were three instances of gastrointestinal disturbance and one flare of RA. Plasma and urinary levels of SSZ and its metabolites showed no statistically significant changes after probiotic administration and the incidence of gastrointestinal disturbance did not appear to be ascribed to higher sulfapyridine plasma levels. Probiotic-specific DGGE bands were detected in the feces of some patients after the treatment period.
Short-term treatment of RA patients with a multi-strain probiotic did not significantly influence SSZ metabolism as has been demonstrated in animal models.
开展一项初步研究，以考察短期口服益生菌给药对稳定服用柳氮磺胺吡啶（SSZ）的类风湿关节炎（RA）患者 SSZ 代谢的影响。
12 例在研究前至少 3 个月稳定服用 SSZ 的 RA 患者，每天两次接受含有 3 株细菌（1.8×10(9)CFU/天）的益生菌制剂治疗 1 周。在益生菌治疗前和治疗后以及停止益生菌治疗 3 周后，分别采集单点血样和 12 小时尿液样，用于测定 SSZ 及其代谢物。通过变性梯度凝胶电泳（DGGE）调查患者粪便中益生菌细菌的存在情况。
记录到的不良事件有 3 例胃肠道不适和 1 例 RA 发作。益生菌给药后，血浆和尿液中 SSZ 及其代谢物水平无统计学意义上的变化，胃肠道不适的发生率似乎与较高的磺胺吡啶血浆水平无关。在治疗期后，一些患者的粪便中检测到了益生菌特异性的 DGGE 条带。
在动物模型中已证实，RA 患者短期使用多菌株益生菌治疗不会显著影响 SSZ 代谢。
